(Q33923878)

30 July 2017

0 references

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis (English)

1 reference

30 July 2017

0 references

Jackson JL

1 reference

30 July 2017

O'Malley PG

1 reference

30 July 2017

Tomkins G

1 reference

30 July 2017

Balden E

1 reference

30 July 2017

Santoro J

1 reference

30 July 2017

Kroenke K

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

American Journal of Medicine

30 July 2017

published in

1 reference

30 July 2017

volume

108

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

65-72

1 reference

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Irritable bowel syndrome in office-based practice in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Role of visceral afferent mechanisms in functional bowel disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable-bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Terminal ileal mucosal mast cells in irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Psychological aspects of irritable bowel syndrome: comparisons with inflammatory bowel disease and nonpatient controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Bias in meta-analysis detected by a simple, graphical test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

A note on graphical presentation of estimated odds ratios from several clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

The file drawer problem and tolerance for null results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Clomipramine and mianserin in chronic idiopathic pain syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Irritable colon and depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Therapeutic usefulness of amitriptyline in spastic colon syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Symptom relief with amitriptyline in the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Effect sizes for interpreting changes in health status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Bran supplementation in the treatment of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Loperamide treatment of the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Anticonvulsant drugs for management of pain: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Sucralfate versus placebo in treatment of non-ulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Sexual and physical abuse in women with functional or organic gastrointestinal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Clinical predictors of mental disorders among medical outpatients. Validation of the "S4" model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Controlled study of psychotherapy in irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Treatment of post-herpetic neuralgia: antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Effects of ascorbic acid on the common cold. An evaluation of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Symptoms and visceral perception in severe functional and organic dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900299-5

10.1016/S0002-9343(99)00299-5

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference